Anavex Life Sciences Corp. Common Stock (AVXL) Stock
NASDAQ · AVXL
Fundamentals
Market cap
$137.19M
Price / Earnings ratio
-10.5x
Price / Book ratio
1.2x
Return on assets
-11.0%
Dividend amount
$0.00
Dividend yield
0.00%
Source: third-party data provider, as of October 15, 2026
Compare with AVXL
Recent news

Business Wire
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
NeutralAVXLOctober 8, 2026
Business WireNeutral
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
AVXL

Business Wire
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
NeutralAVXLOctober 6, 2026
Business WireNeutral
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
AVXL

Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 5, 2026
Business WireNeutral
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL

Business Wire
Law Offices of Howard G. Smith Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 5, 2026
Business WireNeutral
Law Offices of Howard G. Smith Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 19.22
- MACD 12/26/9
- -0.33
- EMA 9 of MACD
- -0.30
- MACD histogram
- -0.03
- SMA 50
- $2.62
- Price below SMA 50
- EMA 50
- $2.33
- Price below EMA 50
- SMA 200
- $3.26
- Price below SMA 200
- EMA 200
- $3.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
125M82M41M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-46.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Business Wire
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
NeutralAVXLOctober 8, 2026
Business WireNeutral
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
AVXL

Business Wire
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
NeutralAVXLOctober 6, 2026
Business WireNeutral
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
AVXL

Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 5, 2026
Business WireNeutral
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL

Business Wire
Law Offices of Howard G. Smith Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 5, 2026
Business WireNeutral
Law Offices of Howard G. Smith Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL

Business Wire
Law Offices of Frank R. Cruz Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 1, 2026
Business WireNeutral
Law Offices of Frank R. Cruz Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL

Business Wire
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
NeutralAVXLOctober 1, 2026
Business WireNeutral
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
AVXL

Business Wire
Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
NeutralAVXLOctober 1, 2026
Business WireNeutral
Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
AVXL

Business Wire
Securities Class Action Filed Against Anavex Life Sciences Corp. – AVXL Investors Encouraged to Contact Kirby McInerney LLP
NeutralAVXLSeptember 30, 2026
Business WireNeutral
Securities Class Action Filed Against Anavex Life Sciences Corp. – AVXL Investors Encouraged to Contact Kirby McInerney LLP
AVXL

Business Wire
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
NeutralAVXLSeptember 30, 2026
Business WireNeutral
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
AVXL

Business Wire
Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – AVXL
NeutralAVXLSeptember 30, 2026
Business WireNeutral
Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – AVXL
AVXL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Anavex Life Sciences Corp. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees34
CEODr. Terrie Kellmeyer Ph.D.
IPO DateAug 2, 2006
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Terrie Kellmeyer Ph.D. | Interim Chief Executive Officer | — |
| Ms. Sandra Boenisch C.P.A., CGA | Principal Financial Officer & Treasurer | 1981 |
Fundamentals
Valuation
Market cap$137.19M
Price-to-book value1.22
Price-earnings ratio-10.50
Return on Equity-11.00%
Return on Assets-11.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-0.15
Income Statement
Average volume1,226,910
EBITDA$-13.00M
1 year high (52w)$9.50
1 year low (52w)$1.44
Dividend
Dividend amount$0.00
Dividend yield0.00%
Source: third-party data provider, as of October 15, 2026
Technical indicators
- RSI 14
- 19.22
- MACD 12/26/9
- -0.33
- EMA 9 of MACD
- -0.30
- MACD histogram
- -0.03
- SMA 50
- $2.62
- Price below SMA 50
- EMA 50
- $2.33
- Price below EMA 50
- SMA 200
- $3.26
- Price below SMA 200
- EMA 200
- $3.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +5.5 | -4.2 | -3.2 | |||||||||
| 2022 | -26.1 | -0.7 | +16.9 | -32.0 | +0.7 | +21.5 | -0.4 | -2.9 | +6.9 | +16.0 | -28.9 | +4.4 |
| 2023 | +12.3 | -13.4 | -11.5 | -4.3 | +12.4 | -10.7 | +3.0 | -3.1 | -17.5 | -12.3 | +28.3 | +23.0 |
| 2024 | -1.3 | -16.4 | -3.6 | -27.3 | +10.0 | +5.0 | +65.5 | -8.5 | +4.0 | +21.7 | +38.3 | +15.2 |
| 2025 | -23.7 | -8.4 | +3.7 | +18.5 | -19.1 | +22.0 | +21.1 | -13.9 | -6.1 | -11.5 | -50.5 | -6.8 |
| 2026 | +27.7 | -2.0 | -32.2 | +7.7 | -8.7 | -13.1 | +6.6 | -5.1 | -29.6 | -21.7 |
Compare stocks
Market cap
$137.19M
-
-
-
Price / Earnings ratio
-10.50
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,226,910
-
-
-
Earnings per share
$-0.15
-
-
-



